T. Rowe Price Associates
TVGN icon

T. Rowe Price Associates’s Tevogen Bio Holdings TVGN Stock Holding History

T. Rowe Price Associates’s Portfolio TVGN Stock Details TVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-373
Closed -$7K – 3197
2025
Q4 		$7K Hold
373
– – ﹤0.01% 3088
2025
Q3 		$15K Hold
373
– – ﹤0.01% 3041
2025
Q2 		$24K Buy
+373
New +$21.2K ﹤0.01% 3044

Other funds holding TVGN

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

T. Rowe Price Associates's TVGN Position: Q1 2026 in Review

T. Rowe Price Associates sold out of Tevogen Bio Holdings (TVGN) in Q1 2026, closing a stake of 373 shares — an estimated $7K sold.

T. Rowe Price Associates first reported a position in TVGN in Q2 2025 and held it in 3 quarters. The position peaked at $24K in Q2 2025. 30 funds tracked by Wall St. Rank hold TVGN as of Q1 2026.

  • T. Rowe Price Associates reported no remaining Tevogen Bio Holdings position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Associates sold 373 Tevogen Bio Holdings shares in Q1 2026, an estimated $7K.
  • T. Rowe Price Associates first reported a position in Tevogen Bio Holdings in Q2 2025 and held it in 3 quarters.
  • T. Rowe Price Associates's Tevogen Bio Holdings position peaked at $24K in Q2 2025.
  • 30 funds tracked by Wall St. Rank held Tevogen Bio Holdings as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.